pANCA and ASCA in Children with IBD-Unclassified, Crohn's Colitis, and Ulcerative Colitis—A Longitudinal Report from the IBD Porto Group of ESPGHAN
暂无分享,去创建一个
G. Veres | N. Afzal | P. Lionetti | K. Kolho | D. Turner | J. Escher | A. Hauer | C. Romano | C. Spray | D. Wilson | C. Martinez-Vinson | Liron Birimberg-Schwartz | K. Karolewska-Bochenek
[1] Helmut Neumann,et al. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. , 2015, World journal of gastroenterology.
[2] G. Veres,et al. ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents , 2013, Journal of pediatric gastroenterology and nutrition.
[3] E. Nimmo,et al. Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics , 2013, Gastroenterology.
[4] M. Kekıllı,et al. Atypical pANCA as a marker of indeterminate colitis for the prediction of ulcerative colitis and crohn’s disease , 2013, Wiener klinische Wochenschrift.
[5] A. Kuna. Serological markers of inflammatory bowel disease , 2013, Biochemia medica.
[6] S. Ng,et al. Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review , 2012, Inflammatory bowel diseases.
[7] F. Klebl,et al. Clinical Utility of Anti‐Glycan Antibodies in Pediatric Crohn's Disease in Comparison with An Adult Cohort , 2012, Inflammatory bowel diseases.
[8] David C Wilson,et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification , 2011, Inflammatory bowel diseases.
[9] Judy H. Cho,et al. Recent insights into the genetics of inflammatory bowel disease. , 2011, Gastroenterology.
[10] J. Lewis. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. , 2011, Gastroenterology.
[11] Simon C. Potter,et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region , 2009, Nature Genetics.
[12] S. Brand. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease , 2009, Gut.
[13] M. Vatn,et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study) , 2009, Scandinavian journal of gastroenterology.
[14] S. Targan,et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] M. Vatn,et al. Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 years. , 2008, Journal of Crohn's & colitis.
[16] T. Molnár,et al. New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort , 2008, The American Journal of Gastroenterology.
[17] K. Van Steen,et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2007, Gut.
[18] A. Darzi,et al. Diagnostic Precision of Anti-Saccharomyces cerevisiae Antibodies and Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease , 2006, The American Journal of Gastroenterology.
[19] Richard E Thompson,et al. Indeterminate colitis: A significant subgroup of pediatric IBD , 2006, Inflammatory bowel diseases.
[20] Dennis Christie,et al. Serum Immune Responses Predict Rapid Disease Progression among Children with Crohn's Disease: Immune Responses Predict Disease Progression , 2006, The American Journal of Gastroenterology.
[21] B. Sands,et al. A male with a pelvic mass , 2004, Gut.
[22] S. Plevy. Do Serological Markers and Cytokines Determine the Indeterminate? , 2004, Journal of clinical gastroenterology.
[23] M. Dubinsky,et al. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[24] P. Rutgeerts,et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. , 2003, Gastroenterology.
[25] P. Rutgeerts,et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease , 2001, American Journal of Gastroenterology.
[26] S. Targan,et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role , 1998, Gut.
[27] S. Targan,et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. , 1996, Gastroenterology.
[28] S. Targan,et al. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. , 1996, Mayo Clinic proceedings.
[29] S. Hanauer,et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. , 1993, The American journal of gastroenterology.
[30] G. Lichtenstein. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour , 2008 .
[31] Y. Yoshida,et al. [Indeterminate colitis]. , 1994, Ryoikibetsu shokogun shirizu.
[32] E. J. Smith. A children's hospital in a medical center , 1947 .